The prevalence of low muscle mass associated with obesity in the USA

Autor: Dana J. Murdock, Ning Wu, Joseph S. Grimsby, Roberto A. Calle, Stephen Donahue, David J. Glass, Mark W. Sleeman, Robert J. Sanchez

Publikováno v: Skeletal Muscle, Vol 12, Iss 1, Pp 1-10 (2022)

Abstract Background Sarcopenia is defined as age-related low muscle mass and function, and can also describe the loss of muscle mass in certain medical conditions, such as sarcopenic obesity. Sarcopenic obesity describes loss of muscle and function i

Externí odkaz: https://doaj.org/article/4f56a81b31534134b1d3d6277a01fa08

Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia: The ODYSSEY HoFH Trial

Autor: Dirk J, Blom, Mariko, Harada-Shiba, Paolo, Rubba, Daniel, Gaudet, John J P, Kastelein, Min-Ji, Charng, Robert, Pordy, Stephen, Donahue, Shazia, Ali, Yuping, Dong, Nagwa, Khilla, Poulabi, Banerjee, Marie, Baccara-Dinet, Robert S, Rosenson

Publikováno v: Journal of the American College of Cardiology. 76(2)

Homozygous familial hypercholesterolemia (HoFH) is characterized by extremely elevated low-density lipoprotein-cholesterol (LDL-C) levels and early onset atherosclerotic cardiovascular disease despite treatment with conventional lipid-lowering treatm

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::491b2d8d0aec219991a47a01ac5cef89
https://pubmed.ncbi.nlm.nih.gov/32646562

Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial

Autor: Paul D. Thompson, Christopher P. Cannon, Eric Bruckert, Franklin J. Zieve, Marie T. Baccara-Dinet, Jian Zhao, Jean Bergeron, Garen Manvelian, Shazia Ali, Terry A. Jacobson, John R. Guyton, Patrick M. Moriarty, Stephen Donahue, Robert Pordy

Publikováno v: Journal of clinical lipidology. 14(1)

Background The 24-week randomized, double-blind ODYSSEY ALTERNATIVE trial (NCT01709513) demonstrated significant low-density lipoprotein cholesterol (LDL-C) reductions with the PCSK9 inhibitor alirocumab vs ezetimibe in statin-intolerant patients, wi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef024f55093bf342d11950da6b5f8bb2
https://pubmed.ncbi.nlm.nih.gov/32192644

Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial

Autor: Corinne Hanotin, Peter B. Jones, Elisabeth Steinhagen-Thiessen, Maurizio Averna, Helen M. Colhoun, Yunling Du, Stephen Donahue, Randall Severance, Michel Farnier

Publikováno v: Farnier, M, Jones, P, Severance, R, Averna, M, Steinhagen-Thiessen, E, Colhoun, H M, Du, Y, Hanotin, C & Donahue, S 2016, ' Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients : The ODYSSEY OPTIONS II randomized trial ', Atherosclerosis, vol. 244, pp. 138-46 . https://doi.org/10.1016/j.atherosclerosis.2015.11.010

OBJECTIVE: To compare lipid-lowering efficacy of adding alirocumab to rosuvastatin versus other treatment strategies (NCT01730053).METHODS: Patients receiving baseline rosuvastatin regimens (10 or 20 mg) were randomized to: add-on alirocumab 75 mg ev

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cfd7c2a81cb71fd157878238361dc5e5

Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies

Autor: Yunling Du, Helen M. Colhoun, Harold E. Bays, Stephen Donahue, Peter B. Jones, Corinne Hanotin, Jennifer G. Robinson

Publikováno v: Clinical Cardiology

The phase 3 ODYSSEY OPTIONS studies (OPTIONS I, NCT01730040; OPTIONS II, NCT01730053) are multicenter, multinational, randomized, double-blind, active-comparator, 24-week studies evaluating the efficacy and safety of alirocumab, a fully human monoclo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4871bff01045ef89e2489464b4c7808
https://pubmed.ncbi.nlm.nih.gov/25269777